ASH 2016: Dr. Wiestner on Ibrutinib Failure with Either Progressive Chronic Lymphocytic Leukemia or Richter’s Transformation

In my interview from ASH 2016 in San Diego, Dr. Adrian Wiestner of the National Institutes of Health talks about the patients who fail ibrutinib due to disease progression. Our interview covers important considerations for all patients when planning chronic lymphocytic leukemia treatment. Take Away Points: Responses to single agent ibrutinib in CLL have been…